Left ventricular dysfunction in ADPKD and effects of octreotide-LAR: A cross-sectional and longitudinal substudy of the ALADIN trial

What Was Tested

The paper reports a study of Octreotide, published as a randomized controlled trial.

In autosomal dominant polycystic kidney disease (ADPKD) cardiac abnormalities have been observed before the onset of hypertension or renal dysfunction.

The researchers sought to characterize, in ADPKD patients, left ventricular (LV) function and its changes after somatostatin-analogue octreotide-LAR treatment.

Who Took Part

The abstract describes 34 patients taking part.

PubMed indexes the participants as adults and middle-aged adults, both men and women.

In a 1:1:1 cross-sectional study, the researchers evaluated LV function by speckle-tracking echocardiography in 34 ADPKD patients from one ALADIN-trial center and in 34 age- and gender-matched healthy controls and 34 equally-matched renal controls with non-cystic chronic kidney disease.

Changes in LV function were compared in the 16 and 18 ADPKD patients originally randomized to 3 year-treatment with octreotide-LAR or placebo, respectively.

How the Study Was Run

In design terms this was a randomized and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Octreotide and who got the comparison, which limits bias.

The comparison arm used a placebo, so changes seen with Octreotide could be set against what happens without it.

What Was Measured

The subject headings attached to it are Antineoplastic Agents, Hormonal, Cross-Sectional Studies, Echocardiography, Doppler, Glomerular Filtration Rate, Heart Ventricles, Octreotide and Polycystic Kidney, Autosomal Dominant.

The authors tagged it with the keywords Left ventricular dysfunction, Renal disease, Somatostatin analogues and Speckle-tracking echocardiography.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Octreotide in 34 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2019 (International journal of cardiology), a journal based in Netherlands.

More context: the Octreotide compound page, all human trials.